Skip to main content
. 2012 Jun;121(5):785–792. doi: 10.1111/j.1471-4159.2012.07716.x

Fig. 2.

Fig. 2

Soluble CD163 in SAH. (a) Serum sCD163 levels in SAH patients (n = 30) and controls (n = 20) (p > 0.05). (b) CSF sCD163 levels in SAH patients (n = 29) and controls (n = 20) (p < 0.0001). (c) BCB compromise in SAH (n = 30) as shown by albumin permeability versus controls (n = 20) (p < 0.001). (d) sCD163 and albumin CSF/serum quotients in SAH (n = 29, p < 0.0001).